FDA Approves 23 E-Cigarette Products in 2022

Feb.01.2023
FDA Approves 23 E-Cigarette Products in 2022
FDA has made progress in improving public health by tightening regulations and approving PMTA applications for tobacco products.

On January 31, Brian King, the director of the Center for Tobacco Products (CTP) at the US Food and Drug Administration (FDA), issued a public letter. In the letter, it was stated that significant progress was made in improving public health by the CTP in 2022 through proposing regulations, reviewing applications for new tobacco products prior to legal sales (PMTA), enforcing compliance, investigating and holding accountable companies that broke the law, and educating the public about the risks of tobacco products. Currently, preparations are underway for 2023.


So far, the FDA has received over 6.7 million applications for e-cigarette products, but has only approved 23 of them. Among them, 3 were approved in 2021 and 20 were approved in 2022, all of which were tobacco flavors.


According to a list, there are 9 products from R.J, a subsidiary of British American Tobacco (BAT), 8 products from Logic, a subsidiary of Japan Tobacco, and 6 products from NJOY LLC that are allowed to be sold on the market.


According to analysis, the primary considerations for FDA's PMTA review of e-cigarette products are the product's harm reduction and safety. Additionally, FDA favors closed and disposable e-cigarettes.


According to reports, NJOY is the third largest e-cigarette brand in the US and the only American e-cigarette company that has passed PMTA certification. Its ceramic chip is exclusively manufactured by SMIC. In July 2022, there were reports that Altria plans to acquire NJOY.


The PMTA has been approved for the following list:


List of products cleared by PMTA in 2021 | Image source: FDA official website


List of 2021 PMTA approvals | Image source: FDA official website


References:


1) Orders have been granted for premarket marketing of tobacco products.


As we reflect on the past year and anticipate the future, we examine the strides made by the FDA in regulating tobacco products in 2022.


Smoore, a leading vape manufacturer, has commented on the recent marketing orders issued by the US FDA. The company expressed flattery at being included in the targeted group for the orders. The FDA has ordered several companies to remove flavored vape products from the market due to concerns that they are targeting youth consumers. Smoore has stated that they will comply with the orders, but also voiced their desire to continue providing customers with quality products while ensuring the safety of all consumers.


E-cigarette maker NJOY is reportedly preparing for a possible sale.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Glas Says FDA Scientific Review Backed Several Flavored Products Before Senior Leaders Blocked Them
Glas Says FDA Scientific Review Backed Several Flavored Products Before Senior Leaders Blocked Them
Glas says newly released internal FDA records show agency scientific reviewers supported authorization for several flavored G2 products before senior leadership halted them. According to documents obtained through a Freedom of Information Act request, FDA’s Office of Science first recommended marketing authorization for all eight products in December 2025 and later supported six of them in February 2026. FDA ultimately authorized only the G2 device and one tobacco-flavored pod in March.
Apr.23 by 2FIRSTS.ai
KT&G Overseas Tobacco Revenue Jumps 24.6%, Attracting Global Capital
KT&G Overseas Tobacco Revenue Jumps 24.6%, Attracting Global Capital
South Korean tobacco company KT&G is drawing growing global investor attention after reporting record overseas tobacco sales, with international institutions including Capital Group and BlackRock increasing their stakes.
Business
May.19
AIR Shares Drop 18.6% in Nasdaq Debut, Testing Hookah’s Move Toward Public Markets
AIR Shares Drop 18.6% in Nasdaq Debut, Testing Hookah’s Move Toward Public Markets
AIR Global’s Nasdaq debut under ticker AIIR ended with a 18.6% first-day decline, giving the global hookah industry a rare public-market reference point. Beyond one company’s share move, the listing raises a broader question: can a culturally rooted, fragmented and venue-based category evolve into a more scalable and investable consumer sector?
Special Report
May.19
FDA Warns Retailers Over Unauthorized Nicotine Pouches Resembling Candy and Everyday Products
FDA Warns Retailers Over Unauthorized Nicotine Pouches Resembling Candy and Everyday Products
The FDA issued warning letters to eight retailers selling unauthorized nicotine pouches and dissolvable tobacco products resembling candy, breath strips and cough drops. The action highlights rising scrutiny of packaging, youth appeal and accidental ingestion risks, as the agency clarifies enforcement priorities for unauthorized ENDS and nicotine pouch products while maintaining PMTA as the legal market pathway.
Special Report
May.21
AIR Expects to Complete CAEP Business Combination in Q2 2026 and List on Nasdaq
AIR Expects to Complete CAEP Business Combination in Q2 2026 and List on Nasdaq
AIR Limited and Cantor Equity Partners III announced that the F-4 registration statement related to their proposed business combination was declared effective by the U.S. Securities and Exchange Commission on April 22, 2026. Under the arrangement first announced on Nov. 7, 2025, the combined company, AIR Global PLC, is intended to list on Nasdaq in the United States under the ticker “AIIR.”
Apr.24 by 2FIRSTS.ai
AP Questions FDA Rationale as Glas Fruit-Flavored Vapes Won Authorization Without Added Cessation Benefit
AP Questions FDA Rationale as Glas Fruit-Flavored Vapes Won Authorization Without Added Cessation Benefit
The U.S. Food and Drug Administration (FDA) recently authorized two fruit-flavored vaping products from Glas, but a newly released agency memo shows the products did not demonstrate greater smoking-cessation benefits than tobacco-flavored e-cigarettes. The Associated Press said the findings are likely to raise further questions about the FDA’s regulatory rationale and standards for flavored vaping products.
Jun.12